Abstract Background Parkinson’s disease (PD) is a progressive neurodegenerative with no cure and few treatment options. Its incidence increasing due to aging populations, longer duration potentially as COVID-19 sequela. Photobiomodulation (PBM) has been successfully used in animal models reduce the signs of PD protect dopaminergic neurons. Objective To assess effectiveness PBM mitigate clinical prospective proof-of-concept study, using combination transcranial remote treatment, order inform...

Parkinson’s disease is the second most common neurodegenerative and increasing in incidence. The combination of motor non-motor symptoms makes this a devastating for people with their care givers. characterised by mitochondrial dysfunction neuronal death substantia nigra, reduction dopamine, accumulation α-synuclein aggregates neuroinflammation. microbiome–gut–brain axis also important disease, involved spread inflammation aggregated α-synuclein. mainstay treatment dopamine replacement...

Insectivorous bats have often been touted as biological control for mosquito populations. However, mosquitoes generally represent only a small proportion of bat diet. Given the size mosquitoes, restrictions imposed on prey detectability by low frequency echolocation, and variable field metabolic rates (FMR), may not be available to or profitable all bats. This study investigated whether consumption was influenced size, which is negatively correlated with echolocation but positively FMR. To...

Responsiveness to low-level laser treatment (LLTT) at a wavelength of 450-910 nm has established it as an effective medical, veterinary and dental chronic pain, inflammation conditions (arthritis macular degeneration), wound repair, lymphoedema, yet the mechanisms underlying effectiveness LLLT remain unclear. However, there is now sufficient evidence from recent research propose integrated model action. The hypothesis presented in this paper that external applications photons (through...

There is a paucity of information on the effect photobiomodulation therapy gut microbiome composition. Parkinson's disease progressive neurological disorder with few management options, although has been suggested as potential avenue treatment. We retrospectively analysed from human stool samples previously published study, which had demonstrated efficacy to treat patients' symptoms. Specifically, we have observed changes in patients after 12-week treatment regimen abdomen, neck, head and...

Emerging evidence is increasingly supporting the use of transcranial photobiomodulation (tPBM) to improve symptoms neurodegenerative diseases, including Parkinson’s disease (PD). The objective this study was analyse safety and efficacy tPBM for PD motor symptoms. a triple blind, randomized placebo-controlled trial with 40 idiopathic patients receiving either active (635 nm plus 810 LEDs) or sham 24 min per day (56.88J), six days week, 12 weeks. primary outcome measures were treatment 37-item...

Objective: To assess whether remote application of photobiomodulation (PBM) is effective in reducing clinical signs Parkinson's disease (PD). Background: PD a progressive neurodegenerative for which there no cure and few treatment options. There strong link between the microbiome-gut-brain axis PD. PBM animal models can reduce protect neurons from damage when applied directly to head or parts body. In study, has been shown improve up 1 year. Methods: Seven participants were treated with...

Parkinson's disease (PD) is the second most common, progressive, and debilitating neurodegenerative associated with aging common movement disorder. Photobiomodulation (PBM), use of non-thermal light for therapeutic purposes using laser or emitting diodes (LED) an emerging non-invasive treatment a diverse range neurological conditions. The main objectives this clinical trial are to investigate feasibility, safety, tolerability, efficacy novel transcranial LED helmet device (the "PDNeuro") in...

Parkinson's disease is a progressive neurological with limited treatment options. Animal models and proof-of-concept case series have suggested that photobiomodulation may be an effective adjunct for the symptoms of disease. The aim was to determine safety feasibility transcranial (tPBM) reduce motor signs disease.In this double-blind, randomised, sham-controlled trial, patients (aged 59-85 years) idiopathic were treated tPBM helmet 12 weeks (72 treatments either active or sham therapy;...

Objective: The objective of this case study was to elucidate the effect photobiomodulation (PBM) on microbiome. Background: gut microbiome has been identified as a key component health, with dysbiosis, characterized by decreased microbial diversity and an altered composition, being recognized instrumental in many diseases disorders. Previous research suggested that can be favorably animal models using PBM. Materials methods: participant had their tested nine occasions, three times before any...

COVID-19 is an evolving pandemic that has far reaching global effects, with a combination of factors makes the virus difficult to contain. The symptoms infection can be devastating or at least very debilitating for vulnerable individuals. It clear elderly are most risk adverse impacts virus, including hospitalization and death. Others those comorbidities such as cardiovascular disease metabolic conditions hyper-excitable immune response. Treatment options acute responses limited there urgent...

Parkinson’s disease is a progressive neurodegenerative with clinical signs and symptoms that deteriorate over time. We have previously demonstrated combination of transcranial remote photobiomodulation treatment has the potential to improve some for up one-year. The objective current study was assess effectiveness continued home three-year period. Eight original twelve participants returned reassessment at 2 years six 3 years. Participants were assessed mobility, fine motor control, balance,...

Background: Parkinson’s disease is an increasingly common neurodegenerative that has a substantial personal, social and economic cost. Although the cardinal symptoms of are motor impairment, non-motor arguably just as important for their effect on quality life. also highly heterogeneous symptom presentation. The mainstay treatment many years been levodopa, more recently dopamine agonists, which can alleviate some symptoms, but have severe side-effects, lose effectiveness over time do not...

Parkinson's disease is a progressive neurodegenerative characterized by clinical motor signs and non-motor symptoms that severely impact quality of life. There an urgent need for therapies might slow, halt or even reverse the progression existing delay onset new symptoms. Photobiomodulation therapy has shown potential to alleviate some in animal studies small trials.